Altamira Therapeutics Announces June 2025 Annual General Meeting

Altamira Therapeutics ( (CYTOF) ) has issued an announcement.

Altamira Therapeutics Ltd. announced its upcoming Annual General Meeting of Shareholders, scheduled for June 11, 2025, in Hamilton, Bermuda. The agenda includes the re-election of four directors and the appointment of BDO AG as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The meeting will also present the financial statements for the year ended December 31, 2024. The board recommends voting in favor of all proposals, and shareholders of record as of May 1, 2025, are entitled to vote at the meeting.

Spark’s Take on CYTOF Stock

According to Spark, TipRanks’ AI Analyst, CYTOF is a Underperform.

Altamira Therapeutics exhibits significant financial and operational challenges, typical of early-stage biotechnology firms, with notable weaknesses in revenue generation and cash flow management. Technical indicators denote a strong bearish trend, with the stock trading well below key moving averages and showing oversold conditions. The lack of valuation metrics and earnings call insights adds to the uncertainty, leading to a cautious and low overall stock score.

To see Spark’s full report on CYTOF stock, click here.

More about Altamira Therapeutics

Altamira Therapeutics Ltd. is a company operating in the pharmaceutical industry, focusing on developing therapeutics and treatments. The company is based in Hamilton, Bermuda, and is involved in creating innovative healthcare solutions.

Average Trading Volume: 9,813

Technical Sentiment Signal: Sell

Current Market Cap: $571K

Learn more about CYTOF stock on TipRanks’ Stock Analysis page.